Skip to main content
ST PHARM CO., LTD. logo

ST PHARM CO., LTD. — Investor Relations & Filings

Ticker · 237690 ISIN · KR7237690003 KO Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2023-10-26 Report Publication Anno…
Country KR South Korea
Listing KO 237690

About ST PHARM CO., LTD.

https://www.stpharm.co.kr/en

ST PHARM CO., LTD. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs). The company provides technology-driven manufacturing services for gene therapies, with core expertise in oligonucleotides and various forms of RNA (xRNA), including messenger RNA (mRNA). In addition to nucleic acid-based medicines, ST Pharm offers custom manufacturing for small molecule APIs. The company's services operate under cGMP (current Good Manufacturing Practice) standards, providing comprehensive solutions that support the entire drug development lifecycle, from research and development to commercial-scale production for its global pharmaceutical partners.

Recent filings

Filing Released Lang Actions
결산실적공시예고
Report Publication Announcement Classification · 100% confidence The document is a short notice titled '결산실적공시 예고' (Notice of Earnings Release) which informs investors about the upcoming date for the release of financial results. It does not contain the actual financial results, but rather announces the schedule for their publication. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of a report is classified as a Report Publication Announcement (RPA).
2023-10-26 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming investor relations (IR) event (a conference call) scheduled for October 31, 2023. It provides details such as the date, time, location (online), and purpose (Q3 2023 earnings call). Since the document is an announcement of an event and the availability of materials rather than the presentation or the financial report itself, it falls under the category of a Report Publication Announcement or general regulatory filing. Given the specific nature of announcing an IR event, 'RPA' is the most accurate classification.
2023-10-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (in this case, the addition of new special related parties due to executive promotions). This type of filing is a mandatory disclosure of significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2023-10-26 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Single Sales/Supply Contract' amendment. It details a change in the contract end date due to a client's request. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into categories like M&A, dividends, or financial reports, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2023-10-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific share counts, percentages, and reasons for changes (such as stock collateral and employee stock ownership). This falls under the category of Major Shareholding Notification.
2023-09-05 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system (KIND) regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) amendment. It details a contract for the supply of pharmaceutical raw materials. Since this is a specific regulatory disclosure regarding a material business contract and does not fit into categories like earnings releases, financial reports, or board changes, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate disclosures.
2023-08-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.